The article, 'Three of the 10 IPOs are bio-companies ... Attraction of Investment 24% ↑' by Chanok Shin (Maeil Economy Newspaper) states the biotechnology industry was a secure growth engine in 2016 and shares achievements made by the bio-industry in 2016, including IPK's out-licensing for 'Thiophene Urea (TU) compound series', a first-in-class hepatitis C virus (HCV) drug candidate. This was highlighted as a major licensing-out achievement, made possible with the financial support from KDDF.


Source: Maeil Economy (December 21, 2016)